title: The first approved agent in the Glitazar's Class: Saroglitazar.
abstract: The new chemical entity (NCE) has been knocked as novel antidiabetic agent, e.g. Saroglitazar. Saroglitazar is a drug for the treatment of Type II diabetes. Saroglitazar is marketed under the trade name Lipaglyn, developed by the Zydus Cadila. Lipaglyn is the first indigenously developed NCE by any Indian pharmaceutical company, ever. Lipaglyn has been approved for the treatment of Type II diabetes by the Drug Controller General of India in June 2013. Lipaglyn is indicated for the patients suffering from diabetes dyslipidemia. It also provides the option of a once-daily oral therapy. Saroglitazar regulates the lipid parameters as well as glycemic control. The present article describes Saroglitazar with its chemical synthesis and patent status with its summary of clinical studies.
authors.affiliation: Department of Chemistry, Shrimant Madhavrao Scindia, Government Model Science College, Jhansi Road, Gwalior, Madhya Pradesh, PIN No. 474001, India. riteshagrawalip@gmail.com.
authors.forename: Ritesh
authors.initials: R
authors.lastname: Agrawal
mesh_terms: D000284:Administration, Oral; D000328:Adult; D017327:Clinical Trials, Phase IV as Topic; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy*; D050171:Dyslipidemias / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000138:chemical synthesis* / Q000737:chemistry; D007194:India; D050356:Lipid Metabolism / Q000187:drug effects; D008875:Middle Aged; D010666:Phenylpropionates / Q000008:administration & dosage* / Q000138:chemical synthesis* / Q000737:chemistry; D011758:Pyrroles / Q000008:administration & dosage* / Q000138:chemical synthesis* / Q000737:chemistry; D055815:Young Adult
chemical_list: D007004:Hypoglycemic Agents; D010666:Phenylpropionates; D011758:Pyrroles; C000588741:saroglitazar